Your browser doesn't support javascript.
loading
Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib.
Selaru, P; Tang, Y; Huang, B; Polli, A; Wilner, K D; Donnelly, E; Cohen, D P.
Affiliation
  • Selaru P; Pfizer Oncology, La Jolla, California, USA.
  • Tang Y; Pfizer Oncology, La Jolla, California, USA.
  • Huang B; Pfizer Oncology, Groton, Connecticut, USA.
  • Polli A; Pfizer Oncology, Milan, Italy.
  • Wilner KD; Pfizer Oncology, La Jolla, California, USA.
  • Donnelly E; Pfizer Oncology, Cambridge, Massachusetts, USA.
  • Cohen DP; Pfizer Oncology, La Jolla, California, USA.
Clin Transl Sci ; 9(2): 63-73, 2016 Apr.
Article in En | MEDLINE | ID: mdl-26841346
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyridines / Drug Discovery / Neoplasms Limits: Humans Language: En Journal: Clin Transl Sci Year: 2016 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyridines / Drug Discovery / Neoplasms Limits: Humans Language: En Journal: Clin Transl Sci Year: 2016 Document type: Article Affiliation country: United States Country of publication: United States